Crinetics Pharmaceuticals Inc (CRNX)
50.75
+0.17
(+0.34%)
USD |
NASDAQ |
Sep 27, 16:00
50.72
-0.03
(-0.06%)
After-Hours: 20:00
Crinetics Pharmaceuticals Research and Development Expense (Annual): 168.53M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 168.53M |
| December 31, 2022 | 130.22M |
| December 31, 2021 | 84.26M |
| December 31, 2020 | 57.00M |
| Date | Value |
|---|---|
| December 31, 2019 | 41.51M |
| December 31, 2018 | 24.48M |
| December 31, 2017 | 9.233M |
| December 31, 2016 | 5.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
41.51M
Minimum
2019
168.53M
Maximum
2023
96.30M
Average
84.26M
Median
2021
Research and Development Expense (Annual) Benchmarks
| PTC Therapeutics Inc | 666.56M |
| Zevra Therapeutics Inc | 39.81M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 5.185M |